Literature DB >> 16248033

Nm 283, an efficient prodrug of the potent anti-HCV agent 2'-C-methylcytidine.

C Pierra1, S Benzaria, A Amador, A Moussa, S Mathieu, R Storer, G Gosselin.   

Abstract

In order to improve the oral bioavailability of 2-C-methylcytidine, a potent anti-HCV agent, the corresponding 3'-O-L-valinyl ester derivative (NM 283) has been synthesized Based on its ease of synthesis and its physicochemical properties, NM 283 has emerged as a promising antiviral drug for treatment of chronic HCV infection.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16248033     DOI： 10.1081/ncn-200060112

Source DB:  PubMed          Journal:  Nucleosides Nucleotides Nucleic Acids        ISSN： 1525-7770            Impact factor:   1.381


  12 in total

1.  Preclinical characterization of GSK2336805, a novel inhibitor of hepatitis C virus replication that selects for resistance in NS5A.

Authors:  Jill Walker; Renae Crosby; Amy Wang; Ermias Woldu; Jessica Vamathevan; Christian Voitenleitner; Shihyun You; Katja Remlinger; Maoshang Duan; Wieslaw Kazmierski; Robert Hamatake
Journal:  Antimicrob Agents Chemother       Date:  2013-10-14       Impact factor: 5.191

2.  Efficacy of 2'-C-methylcytidine against yellow fever virus in cell culture and in a hamster model.

Authors:  Justin G Julander; Ashok K Jha; Jung-Ae Choi; Kie-Hoon Jung; Donald F Smee; John D Morrey; Chung K Chu
Journal:  Antiviral Res       Date:  2010-03-20       Impact factor: 5.970

Review 3.  Drugs in development for hepatitis C.

Authors:  Rudolf E Stauber; Harald H Kessler
Journal:  Drugs       Date:  2008       Impact factor: 9.546

4.  Combinations of 2'-C-methylcytidine analogues with interferon-alpha2b and triple combination with ribavirin in the hepatitis C virus replicon system.

Authors:  Leda Bassit; Jason Grier; Matthew Bennett; Raymond F Schinazi
Journal:  Antivir Chem Chemother       Date:  2008

5.  Efficiency of incorporation and chain termination determines the inhibition potency of 2'-modified nucleotide analogs against hepatitis C virus polymerase.

Authors:  Amy Fung; Zhinan Jin; Natalia Dyatkina; Guangyi Wang; Leo Beigelman; Jerome Deval
Journal:  Antimicrob Agents Chemother       Date:  2014-04-14       Impact factor: 5.191

6.  Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide.

Authors:  Brent E Korba; Menashe Elazar; Ping Lui; Jean-François Rossignol; Jeffrey S Glenn
Journal:  Antimicrob Agents Chemother       Date:  2008-08-18       Impact factor: 5.191

Review 7.  HCV drug discovery aimed at viral eradication.

Authors:  R F Schinazi; L Bassit; C Gavegnano
Journal:  J Viral Hepat       Date:  2009-12-18       Impact factor: 3.728

8.  Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479.

Authors:  Samir Ali; Vincent Leveque; Sophie Le Pogam; Han Ma; Friederike Philipp; Nicole Inocencio; Mark Smith; Andre Alker; Hyunsoon Kang; Isabel Najera; Klaus Klumpp; Julian Symons; Nick Cammack; Wen-Rong Jiang
Journal:  Antimicrob Agents Chemother       Date:  2008-10-06       Impact factor: 5.191

Review 9.  Chutes and ladders in hepatitis C nucleoside drug development.

Authors:  Steven J Coats; Ethel C Garnier-Amblard; Franck Amblard; Maryam Ehteshami; Sheida Amiralaei; Hongwang Zhang; Longhu Zhou; Sebastien R L Boucle; Xiao Lu; Lavanya Bondada; Jadd R Shelton; Hao Li; Peng Liu; Chengwei Li; Jong Hyun Cho; Satish N Chavre; Shaoman Zhou; Judy Mathew; Raymond F Schinazi
Journal:  Antiviral Res       Date:  2013-11-23       Impact factor: 5.970

10.  Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, HCV-796.

Authors:  Anita Y M Howe; Huiming Cheng; Stephen Johann; Stanley Mullen; Srinivas K Chunduru; Dorothy C Young; Joel Bard; Rajiv Chopra; Girija Krishnamurthy; Tarek Mansour; John O'Connell
Journal:  Antimicrob Agents Chemother       Date:  2008-06-16       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.